Edgewise Therapeutics, Inc. (EWTX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Edgewise Therapeutics’ preliminary results for the third fiscal quarter of 2026, reported November 4, 2026, centered on ongoing investment in its muscle-disease small‑molecule programs, including EDG-5506, with operating income at -$46.1 million and operating cash flow at -$77.2 million. Consensus for the next period calls for EPS of -$0.48 on revenue of $9.6 million.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on small-molecule medicines for muscle disease. In qualitative terms, it is an early-stage healthcare developer, and its lead program is EDG-5506, an orally administered compound being studied for dystrophinopathies and other genetically defined muscle conditions.
Today's Snapshot
EWTX closed 1.6% lower at 41.37, in line with a weaker sector. Trading was lighter than usual, with volume about two-fifths of its usual level.
Trading Volume
Below 10d avg (2.1M)
849.6K
vs S&P 500 Today
Underperforming Market
-1.33%
Updated: November 18, 2026 at 21:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$36.37 - $43.27Sell
- RSI (14)48.16Neutral
- Stochastic %K (14, 3, 3)46.88Neutral
- MACD Level (12, 26)1.05Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.